Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to
treat the complications of leptin deficiency in patients with congenital or acquired
generalized lipodystrophy (MYALEPT Prescribing Information). This study is a multicenter,
open-label, Phase 4 trial to provide an assessment of the immunogenicity associated with
metreleptin and of any major potential risks due to development of antibodies to metreleptin.
The study is being conducted to comply with a postmarketing requirement.